|1.||Cesarone, M R: 6 articles (08/2012 - 08/2000)|
|2.||Das, Undurti N: 5 articles (09/2015 - 07/2005)|
|3.||Dezawa, Mari: 5 articles (01/2015 - 01/2012)|
|4.||Kuroda, Yasumasa: 5 articles (01/2015 - 01/2012)|
|5.||Belcaro, G: 5 articles (08/2012 - 08/2000)|
|6.||Pacher, Richard: 5 articles (02/2007 - 02/2002)|
|7.||Goldstein, I: 5 articles (01/2003 - 01/2000)|
|8.||Li, Wei: 4 articles (12/2015 - 08/2013)|
|9.||Wakao, Shohei: 4 articles (04/2014 - 01/2012)|
|10.||Sood, Beena G: 4 articles (01/2014 - 10/2004)|
12/01/2000 - "MUSE was effective and safe in most patients with erectile dysfunction in this study. "
12/01/1998 - "These data of the world-wide longest running prospective trial with a vasoactive drug in self-injection therapy provided impressive proof that Alprostadil-Alfadex represents a very effective and safe treatment for erectile dysfunction of both psychogenic and organogenic origin."
08/01/2001 - "Although MUSE is an appropriate and safe treatment for many patients with erectile dysfunction, the lack of consistency is a significant consideration. "
08/01/2001 - "To determine the consistency of a successful response to intraurethral prostaglandin E(1) (MUSE), an effective treatment for a proportion of patients with erectile dysfunction, during at-home use in men who had a successful response in the office, to define the factors that correlated with the consistency of the response, and to determine whether patients continued long-term use. "
12/01/1997 - "Due to the superior efficacy and lower side-effects self-injection therapy with Alprostadil remains the 'Gold Standard' in the management of male impotence. "
11/01/2013 - "Use of pentoxyfilline or prostaglandin E1 promoted a beneficial effect during intestinal reperfusion, demonstrated by less severe histological lesions in the small intestine mucosa of rats submitted to ischemia and tissue reperfusion when helped by the drugs."
02/01/2003 - "In conclusion, treatment with PGE1 determines a significant improvement in endothelial function in patients with critical limb ischemia."
08/01/1998 - "Further studies are needed to determine the dose that will provide the maximal protective effect and to determine the maximum duration of ischemia against which PGE1 shows protective effects."
01/01/1991 - "Protective effects of prostaglandin E1 on normothermic liver ischemia."
02/01/1989 - "The protective effects of PGE1 on ischemia-related liver damage were evaluated in dogs. "
|3.||Pulmonary Hypertension (Ayerza Syndrome)
01/01/1999 - "These results suggest that administering PGE1 may be effective in the treatment of some forms of pulmonary hypertension in humans."
01/01/1992 - "The infusion of prostaglandin E1, a vasodilating substance with predominant effects on the pulmonary vasculature, has been found effective in the management of pulmonary hypertension associated with various diseases. "
08/01/1995 - "PGE1 may be useful for the treatment of pulmonary hypertension in humans."
04/01/2014 - "Sixty patients with postoperative pulmonary hypertension were divided randomly into 3 groups that received saline, prostaglandin E1, and natriuretic peptide infusions for 12 hours each. "
03/01/2013 - "Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn."
07/01/2005 - "HSPs might therefore play an important role in the protective effects of PGE1 against ischemia/reperfusion injury of the liver."
05/05/2015 - "Myocardial microcirculation of reperfusion injury in patients with STEMI, after primary PCI, can be improved by administering Lipo-PGE1."
09/01/1988 - "It is concluded that PGE1 protects the ischemic myocardium from acute reperfusion injury and that this effect involves an action of the compound on neutrophils, probably by improved myocardial tissue preservation, resulting in reduced formation of chemotactic products and, consequently, less local neutrophil accumulation and release of noxious metabolites."
05/01/2000 - "This study was designed to evaluate the changes in prostanoid concentrations and to delineate the mechanism of the cytoprotective effect of prostaglandin E1 in hepatic ischemia-reperfusion injury. "
11/01/2015 - "Treating hepatic ischaemia-reperfusion injury with alprostadil reduces the risk of early HCC recurrence following LT. "
09/01/2000 - "The 60% of the patients who achieved erection scale 4 or 5 continued to use MUSE until the end of the study, while 40% of them complained of pain at the time of MUSE application, during erection and/or during intercourse. "
01/02/1997 - "The most common side effect was mild penile pain, which occurred after 10.8 percent of alprostadil treatments, but the pain rarely resulted in refusal to continue in the study. "
08/01/2010 - "Participants with CLBP were randomised to a pain biology education and group exercise classes group (EDEX) [n = 20] or a pain biology education only group (ED) [n = 18]. "
12/01/2005 - "Intracavernous PGE1 caused pain in 27% of cases. "
07/01/2005 - "There were no significant differences between PgE1 and Tx with regard to peak cavernous artery flow, time to erection, patients' satisfaction, average axial rigidity and pain. "
|10.||Prostaglandins E (PGE)
|4.||Drug Therapy (Chemotherapy)
|5.||Prostatectomy (Retropubic Prostatectomy)